Clinical Trials Logo

Nicotine Addiction clinical trials

View clinical trials related to Nicotine Addiction.

Filter by:

NCT ID: NCT06291584 Recruiting - Sedentary Behavior Clinical Trials

Effects of Exercises on Functional Capacity

Start date: October 1, 2023
Phase: N/A
Study type: Interventional

In this study, the researchers aim to investigate the effects of strengthening and respiratory exercises on the face and online on functional capacity.

NCT ID: NCT06259630 Withdrawn - Nicotine Addiction Clinical Trials

Nicotine Virtual Reality Conditioned Place Preference

NEVE
Start date: November 3, 2015
Phase: Phase 4
Study type: Interventional

In this between-subjects, placebo controlled, double-blind study, the investigators will examine the effects of low oral doses of nicotine on the learning and extinction of a conditioned place preference acquired in a virtual reality environment by healthy human subjects. Physiological and subjective responses to the drug will also be monitored.

NCT ID: NCT06254001 Recruiting - Tobacco Smoking Clinical Trials

Effectiveness of Combined Tobacco Treatment in Hospitalized Subjects

Start date: January 15, 2024
Phase: Phase 4
Study type: Interventional

In the 20th century, tobacco caused the death of 100 million people worldwide and it is estimated that it will be responsible for 1 billion deaths in the 21st century. Currently 8 million people die each year from smoking, 7 million are associated with active smoking, thus being the main risk factor for loss of disability-adjusted life years for men and the ninth most important risk factor for women. In previous studies it has been reported that approximately 21% (14%-30%) of subjects who have required hospitalization are active smokers, being higher in men than in women (28% vs 14%). The initiation of treatment for smoking cessation in this group of subjects has shown an effectiveness rate of up to 65% to maintain abstinence 6 to 12 months after discharge. The effectiveness has been analyzed in scenarios with only brief advice, in some others with the use of medications such as varenicline, bupropion and nicotine replacement therapy, however, the interventions have not been standardized for adequate analysis, which could contribute to the different results.

NCT ID: NCT05903014 Recruiting - Nicotine Dependence Clinical Trials

Effectiveness of N-Acetylcysteine (NAC) in Motivational Enhancement Therapy for Nicotine Addiction

Start date: January 1, 2023
Phase: Phase 4
Study type: Interventional

The goal of this clinical trial is to determine the effectiveness of the combination of n-acetylcysteine and motivational enhancement therapy on laboratory improvement in the form of changes in blood nicotine, radiological changes in the form of nerve connectivity on post-therapy frontostriatal fMRI examination and clinical changes in the form of abstinence, withdrawal symptoms and cravings in adult smoker.

NCT ID: NCT05897242 Active, not recruiting - Nicotine Dependence Clinical Trials

A Smartphone Application (ACT on Vaping) for Vaping Cessation in Young Adults

Start date: January 3, 2024
Phase: N/A
Study type: Interventional

Almost one in ten young adults report current e-cigarette use, putting them at risk of developing nicotine addiction and long-term health effects of exposure to inhaled toxicants. Despite the need for effective treatments to help these young users quit, very few treatments targeting any type of tobacco use among young adults have been evaluated, particularly for young adults who vape and have unique treatment needs. To address these needs, this trial will evaluate a digital program for young adult e-cigarette users at all stages of readiness to quit called ACT on Vaping.

NCT ID: NCT05530577 Recruiting - Clinical trials for Tobacco Use Disorder

Effects of Semaglutide on Nicotine Intake

Start date: October 7, 2022
Phase: Phase 2
Study type: Interventional

Tobacco use remains the foremost cause of preventable deaths in the U.S. and worldwide. Advancing new smoking cessation therapies, including those targeting novel biological mechanisms, is a critical public health priority. Accumulating evidence from preclinical studies suggests that glucagon-like peptide-1 (GLP-1) receptor agonists reduce intake and/or reinstatement of addictive drugs, including nicotine. However, translational work is necessary to establish whether GLP-1 receptor agonists alter aspects of nicotine response and smoking behavior in smokers. Human laboratory studies play a pivotal role in drug development by providing a time- and cost-efficient means of validating preclinical findings, also providing an ideal platform for studying mechanisms of medication effects. This is an experimental investigation to examine the effects of an approved GLP-1 receptor agonist on nicotine intake and reinstatement. Dependent smokers will be enrolled in a double-blind, parallel-arm trial with laboratory endpoints. Laboratory procedures will include a validated procedure for measuring smoking lapse/reinstatement after overnight abstinence. This study will provide initial laboratory evidence for the potential efficacy of GLP-1 receptor agonists as adjunctive treatments for smoking cessation.

NCT ID: NCT05440721 Withdrawn - Tobacco Dependence Clinical Trials

Clinical Trial of an Innovative Digital Therapeutic for Smoking Cessation With Biochemical Verification

Start date: October 25, 2018
Phase: N/A
Study type: Interventional

This study is evaluating the efficacy of Treatment A for short-term smoking cessation through a blinded randomized controlled trial (RCT) vs.Treatment B.

NCT ID: NCT05434429 Recruiting - Nicotine Dependence Clinical Trials

Mobile Health for Problematic Behaviors and Substance Use

Start date: June 21, 2022
Phase: N/A
Study type: Interventional

The aim of the study is to evaluate the effectiveness of long-term and short-term app-based self-guided psychological interventions to reduce craving and lapse risk in problematic behaviors (compulsive sex, pornography, overeating, gaming, gambling) and substance use (cannabis, nicotine). Participants are randomly assigned to either the intervention group or the control. Participants in the intervention group have access to short-term and long-term interventions, whereas those in the control group only have access to the weekly ecological momentary assessment reports. Participants in the intervention group are able to access the intervention materials 5 days after enrollment and receive weekly ecological momentary assessment reports. Those in the control group will be granted access to all intervention materials after five weeks following study enrollment. A questionnaire battery assessments is administered (1) at baseline in the first week following onboarding in; (2) after 5 weeks; (3) after six months. In addition, longitudinal data on several variables related to craving and lapse risk are collected daily using ecological momentary assessment

NCT ID: NCT05432830 Not yet recruiting - Cigarette Smoking Clinical Trials

Sex Differences in E-cig Perception: Study 1

Start date: April 2024
Phase: N/A
Study type: Interventional

The primary objective is to examine the influence of sex on sensory effects, appeal, and reinforcing value of nicotine containing e-cigs in popular flavor components; sweet and cooling.

NCT ID: NCT05430334 Recruiting - Nicotine Dependence Clinical Trials

Assess the Influence of Nicotine Flux and Nicotine Form on Subjective Effects Related to Dependency

Start date: July 13, 2022
Phase: N/A
Study type: Interventional

Electronic nicotine delivery systems (ENDS) heat and vaporize a nicotine-containing liquid to produce an aerosol that can deliver nicotine to the blood and the brain. ENDS use has increased rapidly in the last decade, especially among youth: over 20% of US high school students are current ENDS users, and there is evidence of nicotine dependence in this population. Federal legislation has been proposed that would restrict ENDS liquid nicotine concentration to make ENDS "significantly less addictive and appealing to youth." However, these and other efforts to curb addiction by limiting nicotine liquid concentration are unlikely to succeed because nicotine emissions from ENDS depend on multiple variables. To achieve the intended public health aims, regulations targeting addiction must focus on nicotine delivery, not nicotine concentration. While nicotine delivery cannot be regulated directly, the rate at which an ENDS emits nicotine, the "nicotine flux", can be regulated and, importantly, predicted based on a few device design and operating variables. However, to date there is no empirical evidence demonstrating the relationship between flux and delivery, nor between flux and the subjective effects that support nicotine dependence. Closing this gap is essential for providing an effective framework for regulating ENDS. At the American University of Beirut, the investigators will assess the relationship between nicotine flux, form, and subjective effects. Participants will use ENDS devices with varying nicotine fluxes and forms. Dependency measures, such as urge to smoke, craving, and abstinence, will be assessed. The outcome will indicate the degree to which nicotine flux/form influence subjective effects related to dependency, puffing intensity, and exposure to toxicants. In summary, this project will provide the empirical evidence needed for public health agencies to use nicotine flux as an encompassing and convenient construct to regulate nicotine delivery from ENDS.